Please assess the completion status of the following clinical trial:

Trial Title: Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmation of adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable~* Progression, intolerance, or contraindication to a fluoropyrimidine (e.g., 5- fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ziv-aflibercept, or ramucirumab), and an anti-PD-1 monoclonal antibody (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins (dMMR) or is microsatellite instability-high (MSI-H)~* For patients with KRAS and NRAS wild-type tumors, progression, intolerance, or contraindication to an anti-EGFR monoclonal antibody (cetuximab or panitumumab)~  * Note: If tissue is known to be positive for HER2 expression (IHC 3+) or the tumor has ERBB2 (HER2) amplification detected by a Clinical Laboratory Improvement Act (CLIA)-certified assay, prior treatment with anti-EGFR therapy is not required~* At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1) that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation~* Life expectancy \>= 3 months per estimation of investigator~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2~* Capable of understanding and complying with the protocol requirements and has signed the informed consent document~* Satisfy at least one of the following two conditions:~  * Willing and able to provide blood sample for screening purposes~ * Guardant 360 testing completed =\< 60 days prior to registration~Exclusion Criteria:~* Evidence within the last 3 years of another malignancy which required systemic treatment. EXCEPTIONS: Non-melanotic skin cancer, carcinoma-in-situ of the cervix, or localized prostate cancer with a current PSA of \< 1.0mg/dL on 2 successive evaluations, at least 90 days apart, with the most recent evaluation no more than 4 weeks prior to registration~* Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee~* History of solid organ transplantation~* Pregnant or planning to become pregnant within the next 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Screening (genetic testing) (Type: None): Patients submit blood samples for genetic testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).